Literature DB >> 23751147

High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia.

Kenji Tokunaga1, Shunichiro Yamaguchi1, Eisaku Iwanaga1, Tomoko Nanri1, Taizo Shimomura2, Hitoshi Suzushima2, Hiroaki Mitsuya1, Norio Asou1.   

Abstract

Alterations in the IKZF1 gene are associated with poor prognosis in pediatric B-cell acute lymphoblastic leukemia (B-ALL). We examined the relationship between IKZF1 alterations and clinical findings in 78 adult patients with B-ALL. Aberrant isoforms of IKZF1 were detected using RT-PCR. The copy numbers of IKZF1 exons and fusion genes caused by exon deletions were determined using RQ-PCR and genomic PCR, respectively. We detected aberrant IKZF1 isoforms in 20 of the 78 patients (13 Ik6 and seven Ik10) and deletions of the entire or parts of the IKZF1 gene in 40 of 70 patients. No IKZF1 point mutations were detected by direct sequencing. Nineteen Ik6 and Ik10 isoforms had been generated through genomic exon deletions, but one through aberrant splicing. In total, 41 of the 78 (52.6%) patients harbored IKZF1 alterations, which were identified in 20 of 24 (83.3%) patients with Philadelphia chromosome (Ph)-positive B-ALL compared with 21 of 54 (38.9%) Ph-negative B-ALL (P = 0.0004). IKZF1 alterations are highly involved even in adults with B-ALL. To fully detect IKZF1 alterations, several methods with alternative approaches are required. To elucidate the clinical significance of IKZF1 alterations in adult B-ALL, our study warrants prospective clinical studies with a full analysis of IKZF1 alterations.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell acute lymphoblastic leukemia; IKZF1; adult

Mesh:

Substances:

Year:  2013        PMID: 23751147     DOI: 10.1111/ejh.12155

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   3.674


  13 in total

1.  Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.

Authors:  J M Boer; A van der Veer; D Rizopoulos; M Fiocco; E Sonneveld; H A de Groot-Kruseman; R P Kuiper; P Hoogerbrugge; M Horstmann; M Zaliova; C Palmi; J Trka; E Fronkova; M Emerenciano; M do Socorro Pombo-de-Oliveira; W Mlynarski; T Szczepanski; K Nebral; A Attarbaschi; N Venn; R Sutton; C J Schwab; A Enshaei; A Vora; M Stanulla; M Schrappe; G Cazzaniga; V Conter; M Zimmermann; A V Moorman; R Pieters; M L den Boer
Journal:  Leukemia       Date:  2015-07-23       Impact factor: 11.528

2.  Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.

Authors:  Judith M Boer; Jasper E Koenders; Bronno van der Holt; Carla Exalto; Mathijs A Sanders; Jan J Cornelissen; Peter J M Valk; Monique L den Boer; Anita W Rijneveld
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

Review 3.  Genetic defects in hematopoietic transcription factors and predisposition to acute lymphoblastic leukemia.

Authors:  Yoshihiro Gocho; Jun J Yang
Journal:  Blood       Date:  2019-07-16       Impact factor: 22.113

4.  Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Authors:  Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; K Martin Kortuem; Laura A Bruins; Jessica E Schmidt; Xiu-Bao Chang; Paul Langlais; Moulun Luo; Patrick Jedlowski; Betsy LaPlant; Kristina Laumann; Rafael Fonseca; P Leif Bergsagel; Joseph Mikhael; Martha Lacy; Mia D Champion; A Keith Stewart
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

5.  Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

Authors:  Sabina Chiaretti; Monica Messina; Sara Grammatico; Alfonso Piciocchi; Anna L Fedullo; Filomena Di Giacomo; Nadia Peragine; Valentina Gianfelici; Alessia Lauretti; Rohan Bareja; Maria P Martelli; Marco Vignetti; Valerio Apicella; Antonella Vitale; Loretta S Li; Cyril Salek; Olivier Elemento; Giorgio Inghirami; David M Weinstock; Anna Guarini; Robin Foà
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

Review 6.  Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia.

Authors:  Michelle L Churchman; Charles G Mullighan
Journal:  Exp Hematol       Date:  2016-11-16       Impact factor: 3.084

7.  Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.

Authors:  Sebastian Giebel; Myriam Labopin; Gerard Socié; David Beauvais; Stefan Klein; Eva Maria Wagner-Drouet; Didier Blaise; Stephanie Nguyen-Quoc; Jean Henri Bourhis; Anne Thiebaut; Hélène Labussière-Wallet; Amandine Charbonnier; Ana Berceanu; José Luis Diez-Martin; Nathalie Fegueux; Jordi Esteve; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-11-25       Impact factor: 5.483

Review 8.  The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia.

Authors:  René Marke; Frank N van Leeuwen; Blanca Scheijen
Journal:  Haematologica       Date:  2018-03-08       Impact factor: 9.941

9.  IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform.

Authors:  Daisuke Harama; Takashi Yahata; Keiko Kagami; Masako Abe; Norie Ando; Shin Kasai; Minori Tamai; Koshi Akahane; Takeshi Inukai; Nobutaka Kiyokawa; Abd Aziz Ibrahim; Kiyoshi Ando; Kanji Sugita
Journal:  Cell Death Discov       Date:  2021-06-11

10.  Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.

Authors:  Qiu-Mei Yao; Kai-Yan Liu; Robert Peter Gale; Bin Jiang; Yan-Rong Liu; Qian Jiang; Hao Jiang; Xiao-Hui Zhang; Mei-Jie Zhang; Shan-Shan Chen; Xiao-Jun Huang; Lan-Ping Xu; Guo-Rui Ruan
Journal:  BMC Cancer       Date:  2016-04-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.